PROVECTUS BIOPHARMACEUTICALS, INC. Quarterly Operating Lease, Right-of-Use Asset in USD from Q1 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Provectus Biopharmaceuticals, Inc. quarterly Operating Lease, Right-of-Use Asset history and growth rate from Q1 2019 to Q3 2024.
  • Provectus Biopharmaceuticals, Inc. Operating Lease, Right-of-Use Asset for the quarter ending September 30, 2024 was $36.7K, a 56.1% decline year-over-year.
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $36.7K -$46.8K -56.1% Sep 30, 2024 10-Q 2024-11-12
Q2 2024 $48.6K -$46.2K -48.7% Jun 30, 2024 10-Q 2024-08-13
Q1 2024 $60.4K -$45.7K -43.1% Mar 31, 2024 10-Q 2024-05-14
Q4 2023 $72K -$45.1K -38.5% Dec 31, 2023 10-Q 2024-11-12
Q3 2023 $83.5K -$44.6K -34.8% Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $94.9K -$44K -31.7% Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $106K +$90.9K +599% Mar 31, 2023 10-Q 2023-05-11
Q4 2022 $117K +$77.6K +196% Dec 31, 2022 10-K 2024-03-28
Q3 2022 $128K +$69.3K +118% Sep 30, 2022 10-Q 2022-11-09
Q2 2022 $139K +$58.1K +71.8% Jun 30, 2022 10-Q 2022-08-11
Q1 2022 $15.2K -$85.6K -84.9% Mar 31, 2022 10-Q 2022-05-12
Q4 2021 $39.6K -$81.3K -67.3% Dec 31, 2021 10-K 2023-03-30
Q3 2021 $58.7K -$80.5K -57.8% Sep 30, 2021 10-Q 2021-11-10
Q2 2021 $80.8K -$76.8K -48.7% Jun 30, 2021 10-Q 2021-08-12
Q1 2021 $101K -$75.6K -42.9% Mar 31, 2021 10-Q 2021-05-11
Q4 2020 $121K -$73.6K -37.8% Dec 31, 2020 10-K 2022-03-29
Q3 2020 $139K -$73K -34.4% Sep 30, 2020 10-Q 2020-11-12
Q2 2020 $158K -$72.4K -31.5% Jun 30, 2020 10-Q 2020-08-12
Q1 2020 $176K -$71.3K -28.8% Mar 31, 2020 10-Q 2020-05-13
Q4 2019 $194K Dec 31, 2019 10-K 2021-03-02
Q3 2019 $212K Sep 30, 2019 10-Q 2019-11-12
Q2 2019 $230K Jun 30, 2019 10-Q 2019-08-08
Q1 2019 $248K Mar 31, 2019 10-Q 2019-05-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.